{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T13:42:53Z","timestamp":1784641373006,"version":"3.55.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T00:00:00Z","timestamp":1659571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T00:00:00Z","timestamp":1659571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s00198-022-06516-6","type":"journal-article","created":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T09:03:32Z","timestamp":1659603812000},"page":"201-206","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Long-term use of burosumab for the treatment of tumor-induced osteomalacia"],"prefix":"10.1007","volume":"34","author":[{"given":"C.","family":"Crotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Zucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Alfieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Caporali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8644-0909","authenticated-orcid":false,"given":"M.","family":"Varenna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,4]]},"reference":[{"key":"6516_CR1","doi-asserted-by":"publisher","first-page":"17044","DOI":"10.1038\/nrdp.2017.44","volume":"3","author":"S Minisola","year":"2017","unstructured":"Minisola S, Peacock M, Fukumoto S, Cipriani C, Pepe J, Tella SH, Collins MT (2017) Tumour-induced osteomalacia. Nat Rev Dis Primers 3:17044. https:\/\/doi.org\/10.1038\/nrdp.2017.44","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"6516_CR2","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1007\/s00223-020-00691-6","volume":"108","author":"P Florenzano","year":"2021","unstructured":"Florenzano P, Hartley IR, Jimenez M, Roszko K, Gafni RI, Collins MT (2021) Tumor-induced osteomalacia. Calcif Tissue Int 108(1):128\u2013142. https:\/\/doi.org\/10.1007\/s00223-020-00691-6","journal-title":"Calcif Tissue Int"},{"issue":"4","key":"6516_CR3","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.afos.2018.12.001","volume":"4","author":"Z Yin","year":"2018","unstructured":"Yin Z, Du J, Yu F, Xia W (2018) Tumor-induced osteomalacia. Osteoporos Sarcopenia 4(4):119\u2013127. https:\/\/doi.org\/10.1016\/j.afos.2018.12.001","journal-title":"Osteoporos Sarcopenia"},{"issue":"10","key":"6516_CR4","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1001\/jama.294.10.1260","volume":"294","author":"SM Jan de Beur","year":"2005","unstructured":"Jan de Beur SM (2005) Tumor-induced osteomalacia. JAMA 294(10):1260\u20131267. https:\/\/doi.org\/10.1001\/jama.294.10.1260","journal-title":"JAMA"},{"key":"6516_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2021.116077","volume":"152","author":"C Crotti","year":"2021","unstructured":"Crotti C, Bartoli F, Coletto LA, Manara M, Marini E, Daolio PA, Parafioriti A, Armiraglio E, Zucchi F, Sinigaglia L, Caporali R, Varenna M (2021) Tumor induced osteomalacia: a single center experience on 17 patients. Bone 152:116077. https:\/\/doi.org\/10.1016\/j.bone.2021.116077","journal-title":"Bone"},{"issue":"7","key":"6516_CR6","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1007\/s00198-017-4007-2","volume":"28","author":"G Gonzalez","year":"2017","unstructured":"Gonzalez G, Baudrand R, Sepulveda MF, Vucetich N, Guarda FJ, Villanueva P, Contreras O, Villa A, Salech F, Toro L, Michea L, Florenzano P (2017) Tumor-induced osteomalacia: experience from a South American academic center. Osteoporos Int 28(7):2187\u20132193. https:\/\/doi.org\/10.1007\/s00198-017-4007-2","journal-title":"Osteoporos Int"},{"issue":"1","key":"6516_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00000478-200401000-00001","volume":"28","author":"AL Folpe","year":"2004","unstructured":"Folpe AL, Fanburg-Smith JC, Billings SD, Bisceglia M, Bertoni F, Cho JY, Econs MJ, Inwards CY, Jan de Beur SM, Mentzel T, Montgomery E, Michal M, Miettinen M, Mills SE, Reith JD, O\u2019Connell JX, Rosenberg AE, Rubin BP, Sweet DE, Vinh TN, Wold LE, Wehrli BM, White KE, Zaino RJ, Weiss SW (2004) Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol 28(1):1\u201330. https:\/\/doi.org\/10.1097\/00000478-200401000-00001","journal-title":"Am J Surg Pathol"},{"issue":"9","key":"6516_CR8","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1097\/PAS.0b013e3181aa2311","volume":"33","author":"A Bahrami","year":"2009","unstructured":"Bahrami A, Weiss SW, Montgomery E, Horvai AE, Jin L, Inwards CY, Folpe AL (2009) RT-PCR analysis for FGF23 using paraffin sections in the diagnosis of phosphaturic mesenchymal tumors with and without known tumor induced osteomalacia. Am J Surg Pathol 33(9):1348\u20131354. https:\/\/doi.org\/10.1097\/PAS.0b013e3181aa2311","journal-title":"Am J Surg Pathol"},{"key":"6516_CR9","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.bone.2014.04.016","volume":"64","author":"S Breer","year":"2014","unstructured":"Breer S, Brunkhorst T, Beil FT, Peldschus K, Heiland M, Klutmann S, Barvencik F, Zustin J, Gratz KF, Amling M (2014) 68Ga DOTA-TATE PET\/CT allows tumor localization in patients with tumor-induced osteomalacia but negative 111In-octreotide SPECT\/CT. Bone 64:222\u2013227. https:\/\/doi.org\/10.1016\/j.bone.2014.04.016","journal-title":"Bone"},{"issue":"10","key":"6516_CR10","doi-asserted-by":"publisher","first-page":"3575","DOI":"10.1210\/jc.2016-2052","volume":"101","author":"D El-Maouche","year":"2016","unstructured":"El-Maouche D, Sadowski SM, Papadakis GZ, Guthrie L, Cottle-Delisle C, Merkel R, Millo C, Chen CC, Kebebew E, Collins MT (2016) (68)Ga-DOTATATE for tumor localization in tumor-induced osteomalacia. J Clin Endocrinol Metab 101(10):3575\u20133581. https:\/\/doi.org\/10.1210\/jc.2016-2052","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"6516_CR11","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1002\/jbmr.1881","volume":"28","author":"WH Chong","year":"2013","unstructured":"Chong WH, Andreopoulou P, Chen CC, Reynolds J, Guthrie L, Kelly M, Gafni RI, Bhattacharyya N, Boyce AM, El-Maouche D, Crespo DO, Sherry R, Chang R, Wodajo FM, Kletter GB, Dwyer A, Collins MT (2013) Tumor localization and biochemical response to cure in tumor-induced osteomalacia. J Bone Miner Res 28(6):1386\u20131398. https:\/\/doi.org\/10.1002\/jbmr.1881","journal-title":"J Bone Miner Res"},{"issue":"3","key":"6516_CR12","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s12020-022-03039-2","volume":"76","author":"L Cianferotti","year":"2022","unstructured":"Cianferotti L, Delli Poggi C, Bertoldo F, Caffarelli C, Crotti C, Gatti D, Giannini S, Gonnelli S, Mazzantini M, Ombretta V, Sella S, Setti A, Varenna M, Zucchi F, Brandi ML (2022) Persistence and recurrence in tumor-induced osteomalacia: a systematic review of the literature and results from a national survey\/case series. Endocrine 76(3):709\u2013721. https:\/\/doi.org\/10.1007\/s12020-022-03039-2","journal-title":"Endocrine"},{"issue":"6","key":"6516_CR13","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s40265-018-0905-7","volume":"78","author":"YN Lamb","year":"2018","unstructured":"Lamb YN (2018) Burosumab: first global approval. Drugs 78(6):707\u2013714. https:\/\/doi.org\/10.1007\/s40265-018-0905-7","journal-title":"Drugs"},{"issue":"2","key":"6516_CR14","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/jbmr.4184","volume":"36","author":"Y Imanishi","year":"2021","unstructured":"Imanishi Y, Ito N, Rhee Y, Takeuchi Y, Shin CS, Takahashi Y, Onuma H, Kojima M, Kanematsu M, Kanda H, Seino Y, Fukumoto S (2021) Interim analysis of a phase 2 open-label trial assessing burosumab efficacy and safety in patients with tumor-induced osteomalacia. J Bone Miner Res 36(2):262\u2013270. https:\/\/doi.org\/10.1002\/jbmr.4184","journal-title":"J Bone Miner Res"},{"issue":"4","key":"6516_CR15","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/jbmr.4233","volume":"36","author":"SM Jan de Beur","year":"2021","unstructured":"Jan de Beur SM, Miller PD, Weber TJ, Peacock M, Insogna K, Kumar R, Rauch F, Luca D, Cimms T, Roberts MS, San Martin J, Carpenter TO (2021) Burosumab for the treatment of tumor-induced osteomalacia. J Bone Miner Res 36(4):627\u2013635. https:\/\/doi.org\/10.1002\/jbmr.4233","journal-title":"J Bone Miner Res"},{"issue":"1","key":"6516_CR16","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jbspin.2019.07.012","volume":"87","author":"AL Day","year":"2020","unstructured":"Day AL, Gutierrez OM, Guthrie BL, Saag KG (2020) Burosumab in tumor-induced osteomalacia: a case report. Joint Bone Spine 87(1):81\u201383. https:\/\/doi.org\/10.1016\/j.jbspin.2019.07.012","journal-title":"Joint Bone Spine"},{"key":"6516_CR17","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT02304367?term=burosumab&cond=Tumor-Induced+Osteomalacia&draw=2&rank=1. Accessed 20\/01\/2022"},{"issue":"11","key":"6516_CR18","doi-asserted-by":"publisher","first-page":"e267","DOI":"10.1515\/cclm-2020-0460","volume":"58","author":"ML Piketty","year":"2020","unstructured":"Piketty ML, Brabant S, Souberbielle JC, Maruani G, Audrain C, Rothenbuhler A, Prie D, Linglart A (2020) FGF23 measurement in burosumab-treated patients: an emerging treatment may induce a new analytical interference. Clin Chem Lab Med 58(11):e267\u2013e269. https:\/\/doi.org\/10.1515\/cclm-2020-0460","journal-title":"Clin Chem Lab Med"},{"issue":"21","key":"6516_CR19","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","volume":"378","author":"TO Carpenter","year":"2018","unstructured":"Carpenter TO, Whyte MP, Imel EA, Boot AM, Hogler W, Linglart A, Padidela R, Van\u2019t Hoff W, Mao M, Chen CY, Skrinar A, Kakkis E, San Martin J, Portale AA (2018) Burosumab therapy in children with X-linked hypophosphatemia. N Engl J Med 378(21):1987\u20131998. https:\/\/doi.org\/10.1056\/NEJMoa1714641","journal-title":"N Engl J Med"},{"issue":"10","key":"6516_CR20","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1002\/jbmr.478","volume":"26","author":"S Wohrle","year":"2011","unstructured":"Wohrle S, Bonny O, Beluch N, Gaulis S, Stamm C, Scheibler M, Muller M, Kinzel B, Thuery A, Brueggen J, Hynes NE, Sellers WR, Hofmann F, Graus-Porta D (2011) FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF-23 signaling and regulating FGF-23 expression in bone. J Bone Miner Res 26(10):2486\u20132497. https:\/\/doi.org\/10.1002\/jbmr.478","journal-title":"J Bone Miner Res"},{"issue":"14","key":"6516_CR21","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1056\/NEJMc2020399","volume":"383","author":"IR Hartley","year":"2020","unstructured":"Hartley IR, Miller CB, Papadakis GZ, Bergwitz C, Del Rivero J, Blau JE, Florenzano P, Berglund JA, Tassone J, Roszko KL, Moran S, Gafni RI, Isaacs R, Collins MT (2020) Targeted FGFR blockade for the treatment of tumor-induced osteomalacia. N Engl J Med 383(14):1387\u20131389. https:\/\/doi.org\/10.1056\/NEJMc2020399","journal-title":"N Engl J Med"},{"key":"6516_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10661","author":"IRRKL Hartley","year":"2022","unstructured":"Hartley IRRKL, Li X, Pozo K, Streit J, del Rivero J, Magone MT, Vold R, Dambkowski CL, Collins MT, Gafni RI (2022) Infigratinib reduces FGF23 and increases blood phosphate in tumor-induced osteomalacia. JBMR Plus. https:\/\/doi.org\/10.1002\/jbm4.10661","journal-title":"JBMR Plus"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-022-06516-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-022-06516-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-022-06516-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,8]],"date-time":"2023-01-08T02:02:38Z","timestamp":1673143358000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-022-06516-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,4]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["6516"],"URL":"https:\/\/doi.org\/10.1007\/s00198-022-06516-6","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,4]]},"assertion":[{"value":"3 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Massimo Varenna has received advisory board honoraria from Kyowa Kirin. Chiara Crotti has received speaker honoraria from Kyowa Kirin. All other authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}